Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 4Terminated 2Recruiting 2Not yet recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Breast Neoplasms 1131Neoplasms 986Carcinoma, Non-Small-Cell Lung 903Prostatic Neoplasms 595Neoplasm Metastasis 529Leukemia, Myeloid, Acute 514Colorectal Neoplasms 492Lung Neoplasms 490Melanoma 488Multiple Myeloma 478Pancreatic Neoplasms 387Lymphoma 370Ovarian Neoplasms 368Recurrence 365Lymphoma, Non-Hodgkin 348Leukemia 340Leukemia, Lymphocytic, Chronic, B-Cell 322Precursor Cell Lymphoblastic Leukemia-Lymphoma 291Head and Neck Neoplasms 276Carcinoma, Renal Cell 276Brain Neoplasms 276Carcinoma, Hepatocellular 261Glioblastoma 250Myelodysplastic Syndromes 244Lymphoma, Large B-Cell, Diffuse 244Squamous Cell Carcinoma of Head and Neck 241Lymphoma, Follicular 236Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190

Interventions

Phlebotomy 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Hydroxyurea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Polycythemia × Clear all
NCT01998828 2020-04-20

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Sierra Oncology LLC - a GSK company

Phase 2 Terminated
39 enrolled
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis

NCT01645124 2012-07-20

CYTO-PV

Consorzio Mario Negri Sud

Phase 3 Terminated
365 enrolled
Myeloid

Polycythemia, Polycythemia Vera, Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡